Medical Animation Anesthetics

Antioxidants Offer Pain Relief In Patients With Chronic Pancreatitis
Antioxidant supplementation was found to be effective in relieving pain and reducing levels of oxidative stress in patients with chronic pancreatitis (CP), reports a new study in Gastroenterology. CP is a progressive inflammatory disease of the pancreas in which patients experience abdominal pain (in early stage) and diabetes and maldigestion (in late stage).

Introducing Abstral(R). Innovative Drug Delivery Technology For Rapid Breakthrough Cancer Pain Management
Abstral® is an important new treatment option for inadequately controlled breakthrough cancer pain (BTcP) in opioid-tolerant cancer patients. The Abstral formulation delivers the analgesic power of fentanyl in a fast dissolving sublingual tablet. Abstral provides rapid relief of BTcP from 10 minutes1, provides predictable dosing2,3 and is convenient and easy to use.

King Pharmaceuticals Initiates Phase II Clinical Trial Evaluating T-62 As A Treatment For Neuropathic Pain
King Pharmaceuticals, Inc. (NYSE: KG) today announced that it has initiated the Phase II clinical trial program evaluating the efficacy and safety of T-62, an oral tablet formulation, the Company's investigational drug for the treatment of neuropathic pain. Dr. Eric Carter, Chief Science Officer of King, stated, "T-62, a new chemical entity, is an adenosine A1 allosteric enhancer that increases the effectiveness of the body's endogenous adenosine to treat neuropathic pain.

Study First To Pinpoint Why Analgesic Drugs May Be Less Potent In Females Than In Males
Investigators at Georgia State University's Neuroscience Institute and Center for Behavioral Neuroscience are the first to identify the most likely reason analgesic drug treatment is usually less potent in females than males. This discovery is a major step toward finding more effective treatments for females suffering from persistent pain.

PAION And ERGOMED Complete Enrolment Of Phase IIa Study With CNS 5161 In Opioid-Refractory Cancer Pain
The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8; London AIM: PAI) and ERGOMED Clinical Research Limited today announce the completion of an open-label, single-centre Phase IIa study with PAION's intravenous NMDA receptor antagonist CNS 5161. The study has been completed by PAION and ERGOMED under a Revenue Sharing and Co-Development Agreement signed in July 2006.

Premature Babies Have Altered Sensory Responses In Later Life
Premature infants who need intensive care or surgery are less sensitive to thermal (hot and cold) sensations later in life, according to research conducted at UCL (University College London). The study, published in the journal Pain, suggests that pain and injury related to major medical interventions in early development may alter how children respond to painful stimuli much later in life.

Humans Make Their Own Salicylic Acid, Aspirin's Active Principle, Say UK Scientists
Scientists in the United Kingdom are reporting new evidence that humans can make their own salicylic acid (SA) - the material formed when aspirin breaks down in the body. SA, which is responsible for aspirin's renowned effects in relieving pain and inflammation, may be the first in a new class of bioregulators, according to a study scheduled for the Dec. 24 issue of ACS' biweekly Journal of Agricultural and Food Chemistry. In the report, Gwendoline Baxter, Ph.D.

The QUIPS Project Aims To Reduce Post Operative Pain
Postoperative pain can be reduced. This has been shown by four of the six hospitals which took part in the project for quality improvement in postoperative pain management (QUIPS). The data from this project from the different hospitals can be compared using a benchmark server, allowing hospitals to identify deficiencies in the care they provide and to learn from other centers.

NeurogesX Announces FDA Acceptance To Review New Drug Application For NGX-4010 To Treat Post Herpetic Neuralgia
NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) to review its investigational product candidate, NGX-4010, for the management of pain due to post-herpetic neuralgia (PHN).

Common Treatment For Men's Pelvic Pain Proves Ineffective, Queen's-led Study Shows
A commonly-prescribed drug for men suffering from a painful pelvic condition failed to significantly reduce patients' symptoms in an international study led by Queen's University professor and urologist at Kingston General Hospital, Curtis Nickel. The drug, called Alfuzosin, is regularly prescribed by more than half of family doctors to treat chronic prostititis/chronic pelvic pain syndrome. This affliction is estimated to affect from six to 12 per cent of the population.

US Air Force Using Medical Acupuncture
Medical acupuncture, which is acupuncture performed by a licensed physician trained at a conventional medical school, is being used increasingly for pain control. Richard Niemtzow, MD, PhD, MPH, Editor-in-Chief of Medical Acupuncture, a peer-reviewed journal http://www.libertpub.com/acu) and the official journal of the American Academy of Medical Acupuncture, is at the forefront of these efforts in the military.

BioDelivery Sciences Submits REMS For ONSOLIS To FDA For Approval
BioDelivery Sciences International, Inc., (NASDAQ:BDSI) announced that it has resubmitted its New Drug Application (NDA) for the company's lead product ONSOLIS™ to the Food and Drug Administration (FDA). The company continues to anticipate that the resubmission, which includes a Risk Evaluation and Mitigation Strategy (REMS) for ONSOLIS, will be approved in the first half of 2009.

New Partnership Between The Journal Of Pain And Symptom Management And The AAHPM
Elsevier, world-leading publisher of scientific, technical, and medical information products and services, is pleased to announce that, beginning in January 2009, the internationally respected Journal of Pain and Symptom Management (JPSM) (http://www.jpsmjournal.com) will be the official journal of the American Academy of Hospice and Palliative Medicine (AAHPM).

Pain Hurts More If The Person Hurting You Means It
Researchers at Harvard University have discovered that our experience of pain depends on whether we think someone caused the pain intentionally. In their study, participants who believed they were getting an electrical shock from another person on purpose, rather than accidentally, rated the very same shock as more painful. Participants seemed to get used to shocks that were delivered unintentionally, but those given on purpose had a fresh sting every time.

QRxPharma Initiates Comparative Study For MoxDuoIR(TM) Dual-Opioid(TM) Pain Therapy
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of therapies for pain and central nervous system (CNS) disorders, announced initiation of a comparative study to evaluate the efficacy and safety profile of MoxDuoIR(TM) against equivalent analgesic doses of morphine and oxycodone alone for the treatment of acute moderate to severe pain.